ProFound AI®
The Clear Leader in Breast AI.
Superior Accuracy and Performance.
FDA Cleared, CE Mark
Book a Meeting
Discover the ProFound impact of our unrivaled 3rd generation artificial intelligence for digital breast tomosynthesis.1
Reading digital breast tomosynthesis (DBT) cases means being able to accurately interpret extensive amounts of data. Clinicians are confronted by the workload and time required to accurately read the data contained in DBT cases.
ProFound AI® is raising the bar on detection performance. It is a high-performing, concurrent-read, cancer-detection and workflow solution that rapidly and accurately analyzes each tomosynthesis image, detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.
Breast AI SuiteBrochurePress ReleaseWhite PaperPodcast
ProFound AI is proven to offer superior clinical performance2
8% improvement in sensitivity7% reduction in rate of recalls52.7% reduction in reading time for radiologists
NEW! ProFound AI 3rd generation performance1,3
Up to 10% improvement in specificity performanceUp to 1% improvement in sensitivityUp to 40% faster processing
The ProFound AI algorithm rapidly and accurately analyzes each individual image or slice and identifies potentially malignant lesions. Trained with one of the largest available 3D image datasets, ProFound AI provides radiologists with crucial information, such as lesion Certainty of Finding and Case Scores, which assists in prioritizing caseload, clinical decision-making and may help to reduce physician burnout.
ProFound AI for Digital Breast Tomosynthesis (DBT) is FDA cleared to offer superior performance and sensitivity to support radiologists in the fight against breast cancer with an unrivaled accuracy of detection.
Benefits to the Patient
Assists in early detection, which can lead to improved outcomes
Reduces false positives/recalls
Improves detection accuracy
Benefits to the Facility
Enhances patient care with improved detection technology
Improves workflow efficiency
Increases diagnostic confidence
Supports mixed tomosynthesis environments
Certainty of Finding and Case Scores
The ProFound AI algorithm is trained to detect malignant soft tissue densities and calcifications. Certainty of Finding and Case Scores are assigned to each detection and each case respectively. Certainty of Finding and Case Scores are relative scores computed by the ProFound AI algorithm and represent the algorithm’s confidence that a detection or case is malignant.
The scores are represented on a 0% to 100% scale. A higher score indicates a higher level of confidence in the malignancy of the detection or case. The Certainty of Finding and Case Scores serve as a guide to the interpreting radiologist to aid in determining if a suspicious finding or case needs further workup.
Certainty of Finding Score
Certainty of Finding Scores are assigned to each detection identified by the ProFound AI algorithm. The score represents how confident the algorithm is that the detection is malignant. Certainty of Findings scores assist in prioritizing caseload and clinical decision-making.
Examples with Certainty of Finding Scores for Soft Tissue Density Detections
85% Certainty of Finding48% Certainty of Finding
Examples with Certainty of Finding Scores for Calcification Detections
97% Certainty of Finding43% Certainty of Finding
Case Score
Case Scores are assigned to each case by the ProFound AI algorithm. The Case Score represents how confident the algorithm is that a case is malignant. All cases, including those without detections, will be assigned a Case Score. Clinicians may use this Case Score information to gain a sense of case complexity, which may be useful for prioritizing the reading work list if supported by the specific work list provider.
iCAD’s product portfolio offers innovative solutions to support breast cancer detection, measure breast density, assess personalized risk, and provide targeted radiation therapy. Our technologies offer clinically proven benefits to clinicians and patients, and are designed to optimize efficiency, enhance the patient experience, and improve outcomes.
- Aligns with the Institute for Health Care Improvement’s Quadruple Aim optimization of health system performance: Better Outcomes, Lower Costs, Enhanced Patient Experience, Improved Clinical Experience.
Platform
ProFound AI for DBT runs on the industry-leading PowerLook® server platform with NVIDIA® Graphical Processing Units (GPU), the latest in powerful GPU technology. PowerLook is a flexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, PACS, and image storage systems. Leveraging the latest in GPU technology, the algorithm can rapidly process a 4-view tomosynthesis case, ensuring results are available to radiologists in the most efficient manner.
Trust the proven leader in Breast AI.
Learn more about how ProFound AI can help you meet your goals.
Thank you. An iCAD representative will contact you shortly.
References:
- iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Marked.
- Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
- Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance, up to 1% improvement in sensitivity, and up to 40% faster processing on the new PowerLook platform.
Products
ProFound AI Risk
ProFound AI for Digital Breast Tomosynthesis
ProFound AI Solutions - EU
ProFound AI Solutions - FR
PowerLook Density Assessment
SecondLook for 2D Mammography
VeraLook Colon Polyp Detection
Resources
ProFound Institute
Educational Webinars
Customer Case Studies
Customer Testimonials
Patient Resources
Compliance
Training & Support
EU Customer Portal
Precise and Powerful Healthcare Solutions
© iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.